Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NVS

Novartis AG ADR

Dec 16 • 04:00PM ET

135.03

-0.16 -0.12 %

Healthcare • Drug Manufacturers - General • Switzerland • NYSE

Peers: PFE MRK JNJ ABBV BMY LLY GILD AMGN REGN VRTX

| Held by: DFIV PPH DFIC DFAI DIHP AVDE DFAX FVD KAT IDVO

Scroll to Statements

Index	-	P/E	18.41	EPS (ttm)	7.33	Insider Own	0.01%	Shs Outstand	1.92B	Perf Week	3.07%
Market Cap	256.23B	Forward P/E	14.76	EPS next Y	9.15	Insider Trans	0.00%	Shs Float	1.90B	Perf Month	2.87%
Enterprise Value	278.92B	PEG	1.83	EPS next Q	1.97	Inst Own	7.14%	Short Float	0.26%	Perf Quarter	10.26%
Income	14.43B	P/S	4.70	EPS this Y	14.39%	Inst Trans	-0.14%	Short Ratio	2.98	Perf Half Y	16.00%
Sales	54.46B	P/B	5.84	EPS next Y	2.39%	ROA	13.69%	Short Interest	4.98M	Perf YTD	38.76%
Book/sh	23.10	P/C	26.27	EPS next 5Y	8.08%	ROE	32.93%	52W High	135.27 -0.18%	Perf Year	36.96%
Cash/sh	5.14	P/FCF	13.02	EPS past 3/5Y	-17.97% 13.96%	ROIC	21.05%	52W Low	96.06 40.57%	Perf 3Y	56.90%
Dividend Est.	4.14 (3.07%)	EV/EBITDA	12.40	Sales past 3/5Y	-0.87% 1.13%	Gross Margin	75.34%	Volatility	1.19% 1.38%	Perf 5Y	55.77%
Dividend TTM	3.87 (2.87%)	EV/Sales	5.12	EPS Y/Y TTM	-15.21%	Oper. Margin	31.75%	ATR (14)	2.26	Perf 10Y	87.49%
Dividend Ex-Date	Mar 12, 2025	Quick Ratio	0.68	Sales Y/Y TTM	11.53%	Profit Margin	26.50%	RSI (14)	63.08	Recom	2.71
Dividend Gr. 3/5Y	14.94% 10.29%	Current Ratio	0.88	EPS Q/Q	27.01%	SMA20	3.40%	Beta	0.50	Target Price	133.51
Payout	55.42%	Debt/Eq	0.72	Sales Q/Q	7.04%	SMA50	4.23%	Rel Volume	1.03	Prev Close	135.19
Employees	75883	LT Debt/Eq	0.55	Earnings	Oct 28 BMO	SMA200	12.36%	Avg Volume	1.67M	Price	135.03
IPO	Nov 07, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.00% 0.24%	Trades		Volume	1,714,731	Change	-0.12%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-08-25	Upgrade	JP Morgan	Neutral → Overweight
Dec-03-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-25-25	Upgrade	BofA Securities	Neutral → Buy
Sep-12-25	Downgrade	Goldman	Neutral → Sell	$118
Aug-08-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$123
Feb-13-25	Downgrade	UBS	Buy → Neutral
Feb-12-25	Initiated	Morgan Stanley	Underweight
Feb-04-25	Upgrade	Deutsche Bank	Hold → Buy
Dec-04-24	Downgrade	HSBC Securities	Hold → Reduce
Sep-11-24	Downgrade	BofA Securities	Buy → Neutral	$135 → $130
Sep-05-24	Downgrade	Goldman	Buy → Neutral
Sep-03-24	Downgrade	Jefferies	Buy → Hold
Jul-19-24	Downgrade	Deutsche Bank	Buy → Hold
May-30-24	Initiated	Goldman	Buy	$120
Feb-23-24	Initiated	BMO Capital Markets	Market Perform	$114
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$114
Jan-16-24	Resumed	UBS	Buy
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Sep-25-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jul-14-23	Initiated	HSBC Securities	Buy

Show Previous Ratings

Today 05:06AM	The Zacks Analyst Blog Microsoft, Novartis, RTX and Air T (Zacks)
Dec-15-25 10:46PM	HSBC Lifts PT on Novartis AG (NVS) to $112 From $106 (Insider Monkey)
04:43PM	Top Research Reports for Microsoft, Novartis & RTX (Zacks)
Dec-12-25 07:26AM	Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report (Insider Monkey)
Dec-11-25 01:48PM	Novartis and UK-based Relation forge R&D deal worth up to $1.7bn (Pharmaceutical Technology)
11:28AM	Loading…
Dec-10-25 11:28AM	Novartis AG (NVS) Gets Upgraded to Overweight from Neutral by JPMorgan (Insider Monkey)
Dec-09-25 03:31PM	Cancer Study Buoys These Small Biotechs (Barrons.com)
11:19AM	Novartis AG (NVS) Announces US FDA Approval of Itvisma (Insider Monkey)
08:57AM	Novartis Drops $1.7 Billion on AI Allergy Breakthrough (GuruFocus.com)
Dec-05-25 09:42AM	Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales? (Zacks)
Dec-04-25 02:02PM	How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter (Investor's Business Daily)
Dec-03-25 09:40AM	Here's Why Novartis (NVS) is a Strong Value Stock (Zacks)
Dec-02-25 04:46PM	ReAlta Life Sciences Designates Dr. Howard Berman as Executive Chairman (Exec Edge)
08:30AM	Janux Therapeutics Stock Craters After 'Positive' Cancer Drug Trial Data. Why It's Down 41%. (Barrons.com)
Dec-01-25 01:33PM	U.S., U.K. Strike Deal on Higher Drug Prices (The Wall Street Journal)
01:09PM	Loading…
Nov-29-25 01:09PM	TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029 (Insider Monkey)
Nov-27-25 09:50AM	Here's Why Novartis (NVS) is a Strong Momentum Stock (Zacks)
Nov-26-25 01:11PM	Novartis axes 550 jobs at Swiss manufacturing site (Pharmaceutical Technology)
11:37AM	Why IBD 50's No. 2 Stock, Travere Therapeutics, Has Doubled In 2025 (Investor's Business Daily)
05:47AM	Novartis cuts hundreds of jobs; Novos dual-acting diabetes drug heading to Phase 3 (BioPharma Dive)
12:00AM	Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ... (GuruFocus.com)
Nov-25-25 07:17PM	Why Novartis Stock Topped the Market Today (Motley Fool)
02:00PM	FDA Greenlights Novartis' Gene Replacement Treatment for SMA (Zacks)
12:28PM	FDA Decision Opens Bigger Market for Novartiss Blockbuster Gene Therapy (Barrons.com)
05:24AM	Novartis secures approval from FDA for Itvisma to treat SMA (Pharmaceutical Business Review)
04:14AM	BofA upgrades Novartis and GSK as pivotal data, new launches approach (Investing.com)
03:00AM	4 takeaways from pharmas manufacturing boom (Pharma Voice)
Nov-21-25 10:15AM	NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth (Zacks)
06:15AM	Novartis Lifts Outlook With Stronger Peak Sales Forecasts (GuruFocus.com)
Nov-20-25 10:49AM	Novartis Hikes Cancer Drug Targets--Signals Billions More in Pipeline Firepower (GuruFocus.com)
05:37AM	Loading…
05:37AM	Novartis Expects Key Drugs, Recent Deals to Buoy Sales Into 2030s (The Wall Street Journal)
01:51AM	Novartis Expects Steady Sales Growth Through 2030 (The Wall Street Journal)
Nov-19-25 10:02PM	Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110 (Insider Monkey)
Nov-17-25 08:30AM	The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet (Newsfile)
Nov-14-25 09:40AM	Here's Why Novartis (NVS) is a Strong Value Stock (Zacks)
Nov-13-25 09:08AM	Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint (Zacks)
Nov-12-25 05:00PM	First New Malaria Drug in Years Performs Strongly in Late-Stage Testing (The Wall Street Journal)
Nov-11-25 05:33AM	Novartis opens California site for RLT manufacturing (Pharmaceutical Business Review)
Nov-08-25 05:28PM	More Drugs to Fight High Cholesterol Are Emerging (The Wall Street Journal)
Nov-06-25 10:03AM	Celcuity Eyeing Cancer Treatment Riddle. Stock Flies 534% This Year. (Investor's Business Daily)
Oct-31-25 09:44AM	Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) (Motley Fool)
Oct-30-25 01:14PM	Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook (Zacks)
Oct-29-25 09:40AM	Why Novartis (NVS) is a Top Value Stock for the Long-Term (Zacks)
08:22AM	What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree? (Zacks)
07:19AM	Analyst Report: Novartis AG (Morningstar Research)
Oct-28-25 05:20PM	Novartis Slips As Generics Bite Into Its Heart-Failure Drug Sales In Mixed Third Quarter (Investor's Business Daily)
02:12PM	Novartis Profit Rises on Cancer Drug Momentum (GuruFocus.com)
11:09AM	INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales (Zacks)
10:14AM	Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition (Zacks)
09:42AM	Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls (The Fly)
09:30AM	Compared to Estimates, Novartis (NVS) Q3 Earnings: A Look at Key Metrics (Zacks)
08:30AM	Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead (The Wall Street Journal)
07:39AM	Stocks to Watch Tuesday: Amazon, Cameco, NextEra, Toyota (The Wall Street Journal)
07:02AM	Earnings Roundup Today: PayPal, UPS, UnitedHealth (The Wall Street Journal)
03:06AM	Novartis Posts Higher Net Profit as Key Drugs Lift Sales (The Wall Street Journal)
Oct-27-25 04:54PM	This biotech's stock soared as investors look for the next buyout target (MarketWatch)
02:48PM	Novartis To Buy Avidity Biosciences In $12 Billion Rare-Disease Deal (GuruFocus.com)
11:16AM	Novartis Avidity Deal Is a Green Light for Biotech Rally (Barrons.com)
09:24AM	Novartis to buy Avidity for $12B, Keurig Dr Pepper raises outlook (Yahoo Finance Video)
08:30AM	Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology (PR Newswire)
08:19AM	USA Rare Earth, Iren, Novartis, Softbank: Trending Stocks (Yahoo Finance Video)
06:49AM	Fed, Tech Earnings and Trump-Xi Talks. Why One Matters Most for Markets. (Barrons.com)
06:19AM	Stocks to Watch Monday: Nvidia, Amazon, Novartis, Keurig Dr Pepper (The Wall Street Journal)
05:26AM	Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal (Investing.com)
04:39AM	Jefferies sees Dyne as key beneficiary of Novartis Avidity buyout (Investing.com)
04:39AM	Novartis Deal Values Avidity Biosciences At $12 Billion (Barrons.com)
Oct-26-25 05:33PM	Novartis Agrees to Acquire Avidity Biosciences for $12 Billion (The Wall Street Journal)
07:24AM	Jim Cramer Says He is a "Buyer of Novartis" (Insider Monkey)
Oct-24-25 10:33AM	Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key (Zacks)
09:57AM	Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards? (Zacks)
09:56AM	REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline? (Zacks)
Oct-23-25 08:26PM	Lightning Round: I'm a buyer of Novartis, says Cramer (CNBC TV)
09:15AM	Gear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key Metrics (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Oct-22-25 12:45PM	Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Oct-20-25 09:30AM	Will Positive Regulatory Updates Further Boost INCY Stock? (Zacks)
Oct-16-25 02:16PM	Novartis Reports Positive Fabhalta Results In IgAN (GuruFocus.com)
08:50AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug (Zacks)
Oct-15-25 09:11AM	Next-Generation Targeted Therapies Reshape Precision Oncology Landscape (PR Newswire)
Oct-13-25 08:50AM	Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio? (Zacks)
08:43AM	Novartis Receives FDA Approval for Rhapsido (remibrutinib) for Chronic Spontaneous Urticaria (Insider Monkey)
06:10AM	Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest? (Motley Fool)
Oct-10-25 11:55AM	Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines? (Zacks)
Oct-09-25 09:37AM	The Zacks Analyst Blog Highlights SAP, Novartis, Philip Morris International, ImmuCell and ClearOne (Zacks)
Oct-08-25 05:07PM	Top Stock Reports for SAP, Novartis & Philip Morris (Zacks)
09:40AM	Here's Why Novartis (NVS) is a Strong Value Stock (Zacks)
08:42AM	3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal (Zacks)
Oct-06-25 12:45PM	3 Reasons Growth Investors Will Love Novartis (NVS) (Zacks)
09:50AM	Why Novartis (NVS) is a Top Momentum Stock for the Long-Term (Zacks)
08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Oct-04-25 09:37AM	2 Surefire Dividend Stocks to Buy for the Long Haul (Motley Fool)
Oct-03-25 08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Oct-02-25 09:15AM	Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue? (Zacks)
Oct-01-25 11:05AM	Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra? (Zacks)
08:20AM	FDA approves Novartis' Rhapsido for CSU treatment (Pharmaceutical Business Review)
Sep-30-25 05:23PM	Novartis receives FDA approval for Rhapsido (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) (PR Newswire)
Sep-29-25 02:01PM	Pharma's Direct-To-Patient Wave Hits Novartis Next (Benzinga)
08:53AM	Novartis to Launch Direct-to-Patient Platform for Cosentyx in U.S. (The Wall Street Journal)
01:39AM	Novartis AG (NVS) To Present New Data on Kesimpta at ECTRIMS 2025 in Barcelona (Insider Monkey)

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Marshall Fiona	Officer	May 23 '25	Proposed Sale	112.68	15,000	1,690,181		May 23 03:40 PM
Kowalski Robert William	Officer	Apr 30 '25	Proposed Sale	113.28	1,212	137,297		Apr 30 01:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVS

Novartis AG ADR

Upgrade your FINVIZ experience